Episode Details

FDA fully approved Lilly's Inluriyo (imlunestrant) plus Verzenio (abemaciclib) after progression in ESR1-mutated advanced breast cancer; evidence is exploratory in 159 patients versus Inluriyo alone, and overall survival remains immature. LEO says FDA accepted dersimelagon's filing with Priority Review—not approval—for light-sensitive EPP and XLP. Novo signed an asset purchase agreement for three Kallyope obesity programs and an Orbis cardiometabolic discovery pact; Electra priced an IPO, and BMS halted Orum's AML/MDS program. CHMP gave MaaT a negative Xervyteg opinion after re-examination in severe gut graft-versus-host disease, while backing Pebrilzo's pertuzumab-biosimilar path and earlier-line Tecvayli monotherapy for multiple myeloma.

Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.